skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

M3 Effect of a ‘defer dispensing inhaled therapy’ programme in an acute hospital trust

Thorax, 2017-12, Vol.72 (Suppl 3), p.A238 [Peer Reviewed Journal]

2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2017 © 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0040-6376 ;EISSN: 1468-3296 ;DOI: 10.1136/thoraxjnl-2017-210983.425

Full text available

Citations Cited by
  • Title:
    M3 Effect of a ‘defer dispensing inhaled therapy’ programme in an acute hospital trust
  • Author: Clark, J ; Eaton, D ; Congleton, J
  • Subjects: Cost control ; Drug stores
  • Is Part Of: Thorax, 2017-12, Vol.72 (Suppl 3), p.A238
  • Description: MethodsOur acute hospital’s spend on inhaled therapy is high, and was rising year on year. It is recognised that ‘stockpiling’ of inhaled therapy occurs, and that patients often don’t bring in their inhalers when admitted acutely. In October 2016 we drew up guidelines for our hospital pharmacists aiming to support them in safely deferring dispensing inhalers, allowing time for patients to arrange for inhalers to be brought in from home. We developed a flow chart, with posters displayed on the medical wards as reminders. In addition we encouraged pharmacists not to dispense a new type of inhaler unless the patient had been assessed as able to use it by the Respiratory Nurse Specialist. From April 2016 we also started actively changing patients from high cost to lower cost devices, matching the local CCG prescribing incentive scheme for 2016–2017.ResultsFollowing the ‘Defer Dispensing’ programme there was a 28% reduction in spend on inhaled therapy and a 6.5% reduction in the number of items dispensed, (See Table). Using 2016–2017 figures the average cost of inhalers dispensed was £14.21, giving a saving of £10 757 related to reduced number of items dispensed. In the first 3 months of this year (2017–2018) there has been an additional 23% cost reduction compared to previous year’s equivalent time period and a 5.2% reduction in number of items dispensed.ConclusionThere is scope to impact on respiratory pharmacy spend in acute trusts. This was achieved both by swapping to lower cost preparations, with ongoing benefit to the local health economy, plus a reduction in the number of items dispensed. We believe that there is potential for further savings by making dispensing of inhaled therapy a more robust process.Abstract M3 Table 1 Financial year Spend on inhaled therapy Change from previous year Number of items dispensed Change from previous year 2014–2015 £1 91 460 11 233 2015–2016 £1 98 624 +£7164 11 671 +438 2016–2017 £1 55 123 -£43 501 10 914 −757
  • Publisher: London: BMJ Publishing Group LTD
  • Language: English
  • Identifier: ISSN: 0040-6376
    EISSN: 1468-3296
    DOI: 10.1136/thoraxjnl-2017-210983.425
  • Source: Alma/SFX Local Collection
    ProQuest Central
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait